Result:Good· Market: Down#Margin expansion#Broad based
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 22.38 | 22.9% | 20.2% |
| Total Income | 22.82 | 23.0% | 19.1% |
| Expenditure | 19.13 | 23.6% | 14.3% |
| PBT | 3.69 | 19.5% | 51.4% |
| Net Profit | 2.72 | 5.4% | 49.1% |
| OPM | 15.50% | 1.02pp | 4.13pp |
| NPM | 11.93% | 2.22pp | 2.40pp |
| EPS | 4.73 | 5.4% | 49.2% |
Revenue +20.2% YoY with PAT +49.1% driven by ~400bps OPM expansion (11.4%→15.5%) rather than one-offs, a solid above-average pharma quarter though not large enough in scale to be a standout.
Informational and educational content only. Not investment advice.